

The pharmaceutical company Biolipox strengthens Board of Directors with experienced industry man

Stockholm

XX October, 2003

The Biolipox' Board of Directors has appointed Mr Håkan Åström as new President of the Board. Biolipox is a pharmaceutical R&D company with a world-class research profile within the field of inflammatory disease, particularly asthma and allergy.

"The opportunity to get involved in the development of Biolipox is very inspiring. I chose Biolipox because the company is active in a field with extended possibilities", says Håkan Åström. "Biolipox' projects have great commercial potential through the collaboration with larger pharma companies", Mr Åström continues.

Håkan Åström was previously Senior VP, Pharmacia Corporation and is presently Director of the Board of both Biovitrum and Scandinavian Life Science AB.

"We are extremely pleased to see Mr Åström join the Board as President. Håkan Åström has many years of experience of building financially solid companies. With a unique understanding of the pharmaceutical industry and an extensive network, after a very successful career within Pharmacia Corporation, Mr Åström enters our company at a very important moment", says Carl-Johan Dalsgaard, CEO of Biolipox. "

Biolipox was founded in 2000 by Professors Hans-Erik Claesson and Magnus Björkholm, both of the Karolinska Institute, after a seed financing by HealthCap. Based on a long tradition of world-leading research in the field of arachidonic acid, Biolipox's current pipeline comprises drugs targeting respiratory inflammatory diseases, particularly allergic rhinitis, and asthma, and inflammatory pain.

The achievements which form the foundation for the understanding of the role of arachidonic acid in inflammatory processes were rewarded with the 1982 Nobel Prize. Professor Bengt Samuelsson, one of the Nobel Prize winners, is a member of the Board at Biolipox.

Biolipox business concept involves producing innovative pharmaceuticals which meet medical needs in inflammatory disease, primarily asthma and pain. This is achieved in collaboration with researchers all over the world. At the point where the efficaciousness of the substances is proven, Biolipox will also be entering into license agreements with the major pharmaceuticals companies on the further development, marketing and sales of the product.

For more information:

Carl-Johan Dalsgaard, CEO; mobile: +46 70 975 98 63

Håkan Åström; phone: +44 1 753 869 769, mobile: +46 703 74 72 13

Biolipox AB is a pharmaceutical R&D company, focused on creating novel, efficacious and cost effective therapeutic opportunities for respiratory conditions and other inflammatory disorders. Biolipox' scientific platform is based on world-class arachidonic acid cascade research, performed at the Karolinska Institutet, and on development of nitric oxide (NO)-releasing drugs. The company has a broad portfolio of potential blockbusters in the respiratory therapy area and unique targets for novel anti-inflammatory and analgesic drugs.

Biolipox AB, Box 6280, SE-102 34 Stockholm, Sweden.

Tel: +46-8-545 28 140, Fax: +46-8-545 28 141, E-mail: carl-johan.dalsgaard@ofco.se

www.biolipox.com